Indication

Congenital athymia

Congenital athymia is an ultra-rare, life-threatening primary immunodeficiency disorder characterized by the complete absence of a functional thymus at birth. Read more about Congenital athymia

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Congenital athymia therapies.

Showing 1–2 of 2 drugs

Filter & compare in the drug finder →Opens the drug finder with Congenital athymia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Congenital athymia.

Congenital athymia is an ultra-rare, life-threatening primary immunodeficiency disorder characterized by the complete absence of a functional thymus at birth.

Primarily affecting pediatric patients, the condition frequently occurs as part of complex genetic syndromes, such as complete DiGeorge syndrome, 22q11.2 deletion syndrome, CHARGE syndrome, or isolated mutations in genes essential for thymic organogenesis, such as FOXN1 or PAX1.

Pathophysiologically, the lack of thymic tissue prevents the maturation and selection of T lymphocytes, resulting in profound T-cell lymphopenia.

Consequently, affected infants present with extreme susceptibility to severe, recurrent infections, failure to thrive, and life-threatening immune dysregulation, including autologous graft-versus-host-like disease.

Personalize your experience

Follow Congenital athymia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it